Filtered By:
Vaccination: AIDS Vaccine
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 167 results found since Jan 2013.
Case Study: Mechanism for Increased Follicular Helper T Cell Development in Activated PI3K Delta Syndrome
This study was carried out after written informed consent from all subjects. All subjects gave written informed consent in accordance with the Declaration of Helsinki. The protocol was approved by the Stanford University and UCLA Institutional Review Boards.
Author Contributions
MB provided patient care and obtained IRB approval. RO prepared histology images. MB, TT, and RB designed the research. TT and LP conducted experiments and analyzed data. MB made the molecular model. MB and TT wrote the manuscript.
Funding
Funding for this work came from the Jeffrey Modell Foundation and from the NIH/NIGMS (R01 GM110482 to MB)....
Source: Frontiers in Immunology - April 11, 2019 Category: Allergy & Immunology Source Type: research
Expanding Research Capacity in Sub-Saharan Africa Through Informatics, Bioinformatics, and Data Science Training Programs in Mali
Conclusion
Bioinformatics and data science training programs in developing countries necessitate incremental and collaborative strategies for their feasible and sustainable development. The progress described here covered decades of collaborative efforts centered on training and research on computationally intensive topics. These efforts laid the groundwork and platforms conducive for hosting a bioinformatics and data science training program in Mali. Training programs are perhaps best facilitated through Africa’s university systems as they are perhaps best positioned to maintain core resources during lapses in sho...
Source: Frontiers in Genetics - April 11, 2019 Category: Genetics & Stem Cells Source Type: research
NIAID Is Dedicated To Saving The Lives Of People With TB
Originally published on niaid.nih.gov
Statement of Christine F. Sizemore, PhD., Richard Hafner, M.D., and Anthony S. Fauci, M.D. National Institute of Allergy and Infectious DiseasesNational Institutes of Health
Tuberculosis (TB) is one of the world’s most devastating infectious diseases. March 24th marks the day in 1882 when German microbiologist Robert Koch announced he had discovered Mycobacterium tuberculosis, the bacterium that causes this ancient scourge. Today, in recognition of World TB Day, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH)...
Source: Healthy Living - The Huffington Post - March 24, 2017 Category: Consumer Health News Source Type: news
La Jolla Institute scientist identifies helper cells that trigger potent responses to HIV
(La Jolla Institute for Allergy and Immunology) A major new finding that will significantly advance efforts to create the world's first antibody-based AIDS vaccine was published today by researchers from the La Jolla Institute for Allergy and Immunology.La Jolla Institute scientist Shane Crotty, Ph.D., a respected vaccine researcher and member of one of the nation's top AIDS vaccine consortiums, showed that certain helper T cells are important for triggering a strong antibody response against HIV, the virus that causes AIDS.
Source: EurekAlert! - Infectious and Emerging Diseases - September 12, 2013 Category: Infectious Diseases Source Type: news
Recent HIV/AIDS News from NIH
October 21, 2013: NIH Officials Map Route Toward an AIDS-Free Generation
“Ending the HIV/AIDS pandemic and achieving an AIDS-free generation will require optimizing the implementation of existing HIV prevention and treatment tools as well as discovering new ones, according to a new commentary from Anthony S. Fauci, M.D., and colleagues at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.”
Read the NIAID press release.
October 17, 2013: NIAID Selects New Director of the Vaccine Research Center
“John R. Mascola, M.D....
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - October 25, 2013 Category: Infectious Diseases Source Type: news
Uh Oh, It's Flu Season! What You Need to Know About Flu Vaccination
Media reports from just about every corner of the country are cautioning that Americans could be in for a particularly intense flu season this year, with many medical experts encouraging folks not to delay getting their flu shots. The flu season is not only here -- it could last until as late as May of next year according to the CDC.
With this in mind, it is helpful to review a few basics that could help keep you, your family and your friends and neighbors feeling at their best during this winter's seasonal outbreaks of the flu.
Who's at Risk?
The flu is a respiratory infection that can cause serious, sometimes life-thr...
Source: Healthy Living - The Huffington Post - December 12, 2014 Category: Consumer Health News Source Type: news
Dr. Fauci at IAS 2015: Comprehensive global prevention can end HIV/AIDS pandemic
(NIH/National Institute of Allergy and Infectious Diseases) Although much progress has been made in combating the global HIV/AIDS pandemic, to halt new infections and end the pandemic, a combination of non-vaccine and vaccine prevention modalities will be needed. Even with these tools, significant implementation gaps must be closed, says Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases at NIH. Dr. Fauci addressed a special session at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Vancouver, Canada.
Source: EurekAlert! - Medicine and Health - July 21, 2015 Category: Global & Universal Source Type: news
NIH Statement on World AIDS Day 2015
Originally posted at NIH News Releases on December 1, 2015
NIH Statement on World AIDS Day 2015
Follow the science to fast-track the end of AIDS.
Anthony S. Fauci, M.D., Director, National Institute of Allergy and Infectious Diseases
Carl Dieffenbach, Ph.D., Director, Division of AIDS, NIAID
Francis S. Collins, M.D., Ph.D., NIH Director
When the first cases of what would become known as AIDS were reported in 1981, scientists and physicians did not know the cause and had no therapies to treat those who were infected. Times have changed and today physicians can offer their patients highly effective medicines that work as bot...
Source: Dragonfly - December 1, 2015 Category: Databases & Libraries Authors: Emily Glenn Tags: News from NIH Public Health Source Type: news
Durable end to the HIV/AIDS pandemic likely will require an HIV vaccine
(NIH/National Institute of Allergy and Infectious Diseases) Despite remarkable gains in the treatment and prevention of HIV infection, development of an effective HIV vaccine likely will be necessary to achieve a durable end to the HIV/AIDS pandemic, according to a new commentary from Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
Source: EurekAlert! - Medicine and Health - October 9, 2017 Category: International Medicine & Public Health Source Type: news
Prefusion Coronavirus Spike Proteins and Their Use
Coronaviruses (CoVs) can cause severe respiratory disease with high fatality rates in humans. The 2002-2003 SARS-CoV epidemic resulted in 8098 cases and 744 deaths, and MERS-CoV, which emerged in 2012, has resulted in 2144 cases and over 750 deaths as of March 2018. Currently, there are no effective prophylactic or therapeutic measures, and because other CoVs are poised to emerge as new human pathogens, there is a need to define a general CoV vaccine solution. Past efforts to develop CoV vaccines have used whole-inactivated virus, live-attenuated virus, recombinant protein subunit, or genetic approaches.CoV spike (S) prote...
Source: NIH OTT Licensing Opportunities - October 12, 2018 Category: Research Authors: ajoyprabhu3 Source Type: research
Middle East Respiratory Syndrome Coronavirus Antibodies
Middle East Respiratory Syndrome coronavirus (MERS-CoV) causes a highly lethal pulmonary infection with ~35% mortality. Currently there are no prophylactic measures or effective therapies. Inventors at the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases have identified and developed neutralizing monoclonal antibodies (nMAbs) against the MERS-CoV. This invention describes antibodies that target the Spike (S) glycoprotein on the coronavirus surface, which mediates viral entry into host cells. These novel antibodies target different regions of the S protein, and when administered in combin...
Source: NIH OTT Licensing Opportunities - November 5, 2018 Category: Research Authors: ajoyprabhu3 Source Type: research
Antigen-Specific Single B Cell Sorting and Monoclonal Antibody Cloning in Guinea Pigs
This study was supported by NIH/NIAID grants R01AI102766 (YL), P01AI104722 (RW and YL), UM1 AI100663 (RW), and Bill and Melinda Gates Foundation grant OPP1084519 (RW). JS is a trainee of NIH training grant T32AI125186A to Anne Simon at University of Maryland, College Park. This study was also partially funded by the International AIDS Vaccine Initiative (IAVI) (RW) with the generous support of United States Agency for International Development (USAID), and Ministry of Foreign Affairs of the Netherlands.
Conflict of Interest Statement
The authors declare that the research was conducted in the absence of any commercial or ...
Source: Frontiers in Microbiology - April 22, 2019 Category: Microbiology Source Type: research
Prefusion Coronavirus Spike Proteins and Their Use
Coronaviruses (CoVs) can cause severe respiratory disease with high fatality rates in humans. The 2002-2003 SARS-CoV epidemic resulted in 8098 cases and 744 deaths, and MERS-CoV, which emerged in 2012, has resulted in 2144 cases and over 750 deaths as of March 2018. Currently, there are no effective prophylactic or therapeutic measures, and because other CoVs are poised to emerge as new human pathogens, there is a need to define a general CoV vaccine solution. Past efforts to develop CoV vaccines have used whole-inactivated virus, live-attenuated virus, recombinant protein subunit, or genetic approaches.CoV spike (S) prote...
Source: NIH OTT Licensing Opportunities - October 12, 2018 Category: Research Authors: ajoyprabhu3 Source Type: research
Improved Live-Attenuated Vaccine for Respiratory Syncytial Virus (RSV) Bearing Codon-Pair Deoptimized NS1, NS2, N, P, M and SH Genes and Additional Point Mutations in the P Gene
RSV is the most important viral agent of severe respiratory disease in infants and young children worldwide and also causes substantial morbidity and mortality in older adults. RSV is estimated to cause more than 33 million lower respiratory tract illnesses, three million hospitalizations, and nearly 200,000 childhood deaths worldwide annually, with many deaths occurring in developing countries. However, despite the prevalence of RSV and the dangers associated with infection, no RSV vaccine has been successfully developed to date. Accordingly, there is a public health need for RSV vaccines.This vaccine candidate comprises ...
Source: NIH OTT Licensing Opportunities - February 25, 2021 Category: Research Authors: ott-admin Source Type: research
HIV Vaccine Findings Will Provide New Options For Vaccine Designers To Strengthen The Drug
Four years ago, a potential HIV vaccine showed promise against the virus that causes AIDS, but it fell short of providing the broad protection necessary to stem the spread of disease. Now researchers -- led by Duke Medicine and including team members from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health, the U.S. Military HIV Research Program and the Thailand Ministry of Health -- have gained additional insights into the workings of the vaccine that help explain why it benefited a third of recipients and left others vulnerable...
Source: Health News from Medical News Today - January 12, 2013 Category: Consumer Health News Tags: HIV / AIDS Source Type: news
